HLA-G1 and HLA-G5 active dimers are present in malignant cells and effusions: The influence of the tumor microenvironment

European Journal of Immunology

Volumn 42, Issue 6, 2012, Pages 1599-1608

  Zilberman, Sonia ^a,b,c   Schenowitz, Chantal ^a,b   Agaugué, Sophie ^a,b   Benoît, Favier ^a,b   Riteau, Béatrice ^d,e   Rouzier, Roman ^c   Carosella, Edgardo D ^a,b   Rouas Freiss, Nathalie ^a,b   Menier, Catherine ^a,b  

^a DIF   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITÉ LYON 1   (France)

^e UMR ASTRE   (France)

Author keywords

Cancer; Dimers; HLA G; Malignant effusions; Tumor microenvironment

Indexed keywords

BETA INTERFERON; DIMER; GAMMA INTERFERON; HLA G ANTIGEN; HLA G1 ANTIGEN; HLA G5 ANTIGEN; INTERLEUKIN 10; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL FUNCTION; CONTROLLED STUDY; CYTOLYSIS; DIMERIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT ASCITES; NATURAL KILLER CELL; OLIGOMERIZATION; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION;

BETA 2-MICROGLOBULIN; CELL LINE, TUMOR; HLA-G ANTIGENS; HUMANS; INTERFERON-BETA; INTERFERON-GAMMA; KILLER CELLS, NATURAL; NEOPLASMS; PROTEIN MULTIMERIZATION; TUMOR MICROENVIRONMENT;

EID: 84862121825     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201141761     Document Type: Article

References (52)

1. Carosella, E. D., Gregori, S., Rouas-Freiss, N., Lemaoult, J., Menier, C. and Favier, B., The role of HLA-G in immunity and hematopoiesis. Cell. Mol. Life Sci. 2010. 68: 353-368.
2. Menier, C., Rouas-Freiss, N., Favier, B., Lemaoult, J., Moreau, P. and Carosella, E. D., Recent advances on the non-classical major histocompatibility complex class I HLA-G molecule. Tissue Antigens 2010. 75: 201-206.
3. Carosella, E. D., Moreau, P., Le Maoult, J., Le Discorde, M. and Rouas-Freiss, N., HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv. Immunol. 2003. 81: 199-252.
4. Menier, C., Rabreau, M., Challier, J. C., Le Discorde, M., Carosella, E. D. and Rouas-Freiss, N., Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. Blood 2004. 104: 3153-3160.
5. Carosella, E. D., Moreau, P., Lemaoult, J. and Rouas-Freiss, N., HLA-G: from biology to clinical benefits. Trends Immunol. 2008. 29: 125-132.
6. Rouas-Freiss, N., Moreau, P., Menier, C., LeMaoult, J. and Carosella, E. D., Expression of tolerogenic HLA-Gmolecules in cancer prevents antitumor responses. Semin. Cancer Biol. 2007. 17: 413-421.
7. Kovats, S., Main, E. K., Librach, C., Stubblebine, M., Fisher, S. J. and DeMars, R., A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990. 248: 220-223.
8. Rouas-Freiss, N., Goncalves, R. M., Menier, C., Dausset, J. and Carosella, E. D., Direct evidence to support the role of HLA-Gin protecting the fetus from maternal uterine natural killer cytolysis. Proc. Natl. Acad. Sci. USA 1997. 94: 11520-11525.
9. Cosman, D., Fanger, N., Borges, L., Kubin, M., Chin, W., Peterson, L. and Hsu, M.-L., A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997. 7: 273-282.
10. Colonna, M., Navarro, F., Bellon, T., Llano, M., Samaridis, J., Angman, L., Cella, M. et al., A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med. 1997. 186: 1809-1818.
11. Menier, C., Riteau, B., Carosella, E. D. and Rouas-Freiss, N., MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int. J. Cancer 2002. 100: 63-70.
12. Shiroishi, M., Tsumoto, K., Amano, K., Shirakihara, Y., Colonna, M., Braud, V. M., Allan, D. S. et al., Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc. Natl. Acad. Sci. USA 2003. 100: 8856-8861.
13. Ristich, V., Liang, S., Zhang, W., Wu, J. and Horuzsko, A., Tolerization of dendritic cells by HLA-G. Eur. J. Immunol. 2005. 35: 1133-1142.
14. Gonen-Gross, T., Achdout, H., Gazit, R., Hanna, J., Mizrahi, S., Markel, G., Goldman-Wohl, D. et al., Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J. Immunol. 2003. 171: 1343-1351.
15. Gonen-Gross, T., Achdout, H., Arnon, T. I., Gazit, R., Stern, N., Horejsi, V., Goldman-Wohl, D. et al., The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecules. J. Immunol. 2005. 175: 4866-4874.
16. Apps, R., Gardner, L., Sharkey, A. M., Holmes, N. and Moffett, A., A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. Eur. J. Immunol. 2007. 37: 1924-1937.
17. Li, C., Houser, B. L., Nicotra, M. L. and Strominger, J. L., HLA-G homodimer-induced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cells. Proc. Natl. Acad. Sci. US A 2009. 106: 5767-5772.
18. Boyson, J. E., Erskine, R., Whitman, M. C., Chiu, M., Lau, J. M., Koopman, L. A., Valter, M. M. et al., Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc. Natl. Acad. Sci. U S A 2002. 99: 16180-16185.
19. Clements, C. S., Kjer-Nielsen, L., Kostenko, L., Hoare, H. L., Dunstone, M. A., Moses, E., Freed, K. et al., Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. Proc. Natl. Acad. Sci. USA 2005. 102: 3360-3365.
20. Gonen-Gross, T. and Mandelboim, O., HLA-G complexes are observed on the cell surface. Hum. Immunol. 2007. 68: 227-232.
21. Shiroishi, M., Kuroki, K., Ose, T., Rasubala, L., Shiratori, I., Arase, H., Tsumoto, K. et al., Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J. Biol. Chem. 2006. 281: 10439-10447.
22. Morales, P. J., Pace, J. L., Platt, J. S., Langat, D. K. and Hunt, J. S., Synthesis of beta(2)-microglobulin-free, disulphide-linked HLA-G5 homodimers in human placental villous cytotrophoblast cells. Immunology. 2007. 122: 179-188.
23. Paul, P., Rouas-Freiss, N., Khalil-Daher, I., Moreau, P., Riteau, B., Le Gal, F. A., Avril, M. F. et al., HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. USA 1998. 95: 4510-4515.
24. Ibrahim, E. C., Aractingi, S., Allory, Y., Borrini, F., Dupuy, A., Duvillard, P., Carosella, E. D. et al., Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype. Int. J. Cancer 2004. 108: 243-250.
25. Rouas-Freiss, N., Moreau, P., Menier, C. and Carosella, E. D., HLA-G in cancer: a way to turn off the immune system. Semin. Cancer Biol. 2003. 13: 325-336.
26. Rouas-Freiss, N., Bruel, S., Menier, C., Marcou, C., Moreau, P. and Carosella, E. D., Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis. Int. J. Cancer 2005. 117: 114-122.
27. D'Urso, C. M., Wang, Z. G., Cao, Y., Tatake, R., Zeff, R. A. and Ferrone, S., Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J. Clin. Invest. 1991. 87: 284-292.
28. Riteau, B., Rouas-Freiss, N., Menier, C., Paul, P., Dausset, J. and Carosella, E. D., HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J. Immunol. 2001. 166: 5018-5026.
29. Moreau, P., Adrian-Cabestre, F., Menier, C., Guiard, V., Gourand, L., Dausset, J., Carosella, E. D. et al., IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int. Immunol. 1999. 11: 803-811.
30. Sekulic, A., Haluska, P., Jr., Miller, A. J., Genebriera De Lamo, J., Ejadi, S., Pulido, J. S., Salomao, D. R. et al., Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin. Proc. 2008. 83: 825-846.
31. Fecher, L. A., Amaravadi, R. K. and Flaherty, K. T., The MAPK pathway in melanoma. Curr. Opin. Oncol. 2008. 20: 183-189.
32. Le Rond, S., Le Maoult, J., Creput, C., Menier, C., Deschamps, M., Le Friec, G., Amiot, L. et al., Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients. Eur. J. Immunol. 2004. 34: 649-660.
33. Seliger, B., Maeurer, M. J. and Ferrone, S., Antigen-processing machinery breakdown and tumor growth. Immunol. Today 2000. 21: 455-464.
34. Hicklin, D. J., Wang, Z., Arient, F., Rivoltini, L., Parmiani, G. and Ferrone, S., Beta 2-microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J. Clin. Invest 1998. 101: 2720-2729.
35. Menier, C., Rouas-Freiss, N. and Carosella, E. D., The HLA-G non classical MHC class I molecule is expressed in cancer with poor prognosis. Implications in tumour escape from immune system and clinical applications. Atlas Genet. Cytogenet. Oncol. Haematol. 2009. 13: 879-900.
36. Rajagopalan, S. and Long, E. O., A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 1999. 189: 1093-1100.
37. Morel, E. and Bellon, T., HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j. J. Immunol. 2008. 181: 2368-2381.
38. Favier, B., Lemaoult, J., Lesport, E. and Carosella, E. D., ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. Faseb J. 2010. 24: 689-699.
39. Singer, G., Rebmann, V., Chen, Y. C., Liu, H. T., Ali, S. Z., Reinsberg, J., McMaster, M. T. et al., HLA-G is a potential tumor marker in malignant ascites. Clin. Cancer Res. 2003. 9: 4460-4464.
40. Davidson, B., Elstrand, M. B., McMaster, M. T., Berner, A., Kurman, R. J., Risberg, B., Trope, C. G. et al., HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol. Oncol. 2005. 96: 42-47.
41. Peracaula, R., Barrabes, S., Sarrats, A., Rudd, P. M. and de Llorens, R., Altered glycosylation in tumours focused to cancer diagnosis. Dis. Markers 2008. 25: 207-218.
42. Saldova, R., Wormald, M. R., Dwek, R. A. and Rudd, P. M., Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis. Markers 2008. 25: 219-232.
43. Morandi, F., Levreri, I., Bocca, P., Galleni, B., Raffaghello, L., Ferrone, S., Prigione, I. et al., Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 2007. 67: 6433-6441.
44. Liang, S., Ristich, V., Arase, H., Dausset, J., Carosella, E. D. and Horuzsko, A., Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6-STAT3 signaling pathway. Proc. Natl. Acad. Sci. USA 2008. 105: 8357-8362.
45. Naji, A., Le Rond, S., Durrbach, A., Krawice-Radanne, I., Creput, C., Daouya, M., Caumartin, J. et al., CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood 2007. 110: 3936-3948.
46. Selmani, Z., Naji, A., Zidi, I., Favier, B., Gaiffe, E., Obert, L., Borg, C. et al., Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3 +regulatory T cells. Stem Cells 2008. 26: 212-222.
47. Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Thery, C., Masurier, C., Flament, C. et al., Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 2001. 7: 297-303.
48. Robertson, M. J., Cochran, K. J., Cameron, C., Le, J. M., Tantravahi, R. and Ritz, J., Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol. 1996. 24: 406-415.
49. Lesport, E., Baudhuin, J., Sousa, S., LeMaoult, J., Zamborlini, A., Rouas-Freiss, N., Carosella, E. D. et al., Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer. Cell. Mol. Life Sci. 2011. 68: 3385-3399.
50. Paul, P., Rouas-Freiss, N., Moreau, P., Cabestre, F. A., Menier, C., Khalil-Daher, I., Pangault, C. et al., HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum. Immunol. 2000. 61: 1177-1195.
51. Menier, C., Saez, B., Horejsi, V., Martinozzi, S., Krawice-Radanne, I., Bruel, S., Le Danff, C. et al., Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum. Immunol. 2003. 64: 315-326.
52. Menier, C., Guillard, C., Cassinat, B., Carosella, E. D. and Rouas-Freiss, N., HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera. Leukemia 2008. 22: 578-584.